Display Settings:

Format

Send to:

Choose Destination
    Therapie. 2007 Mar-Apr;62(2):87-90. Epub 2007 Jun 21.

    [Pharmacokinetic-pharmacodynamics relationships of imatinib (Glivec)].

    [Article in French]

    Source

    Service d'oncologie, Hôpital Henri-Mondor, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil Cedex, France. catherine.delbaldo@hmn.aphp.fr

    Abstract

    Imatinib (Glivec) is a specific inhibitor of tyrosine kinase receptor, in particular of the proto-oncogene c-kit. Proto-oncogene c-kit is expressed or mutated in stromal digestive tumors (GIST). Pharmacokinetic (PK) analysis showed that imatinib displayed linear PK in patients with advanced GIST. Imatinib is extensively metabolized by the cytochrome P450 enzyme system. Alpha-1-acid glycoprotein (AAG), a protein involved in the acute phase of inflammation, is implicated in protein binding of imatinib and seems to play a key role in imatinib PK.

    PMID:
    17582306
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for EDP Sciences

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk